US Edition
Salipro Biotech and Daewoong Pharmaceutical Announce Collaboration Agreement to Advance Development of Novel Therapeutics
- Salipro Biotech and Daewoong Pharmaceutical have entered into a collaboration agreement to develop new therapeutic drugs using the Salipro® platform.
- This partnership is Salipro Biotech's first collaboration with a South Korean partner, highlighting the global application of their expertise.
- The collaboration aims to stabilize challenging drug targets and advance Daewoong Pharmaceutical's drug discovery programs focused on small molecule therapeutics.
- Daewoong Pharmaceutical plans to leverage Salipro Biotech's knowledge and platform for developing therapeutic small molecules against difficult membrane protein targets.
71 Articles
71 Articles
Salipro Biotech and Daewoong Pharmaceutical Announce Collaboration Agreement to Advance Development of Novel Therapeutics
The collaboration combines Salipro Biotech's unique expertise and its Salipro® platform technology to stabilize a challenging drug target and advance Daewoong Pharmaceutical's drug discovery programs for the generation of small molecule drugs. SEOUL, South Korea, June 11, 2025 /PRNewswire/ -- Swedish biotech company Salipro Biotech AB today announced that it has entered into a research collaboration with Daewoong Pharmaceutical Co., Ltd. Daewoon…
Salipro Biotech collaborates with Daewoong for new therapies
The partnership grants Daewoong access to Salipro’s expertise and platform specifically designed for stabilising challenging membrane proteins such as G protein-coupled receptors (GPCRs), ion channels, and transporters. The The post Salipro Biotech collaborates with Daewoong for new therapies development appeared first on Pharmaceutical Business review.
Defensive values have outperformed the market since the beginning of the year in Europe, with the exception of pharmaceuticals, which were plummeted by Donald Trump. Valuations, incorporating bad news, and the defensive profile make it a target of choice for many managers, despite volatility.
Coverage Details
Bias Distribution
- 68% of the sources are Center
To view factuality data please Upgrade to Premium
